Harvey Tatum, MD
Gastroenterology · Tulsa, OKNPI 1659333623
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Gilead at 45.2% of the total. Reporting peaked in 2019 at $13,832 and has fallen 92.8% since, to $991 in 2025. Among gastroenterology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $76.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$12K
- AbbVie$11K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$697
- Johnson & Johnson$608
- Pfizer$457
- Takeda Pharmaceuticals U.S.A., Inc.$386
- plus $2K from 26 others
Across 1,233 payments — averaging $2059.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$993K
- Vanda Pharmaceuticals Inc.$794K
- Takeda Pharmaceuticals U.S.A., Inc.$347K
- Gilead$141K
- Novartis$87K
- Genentech, Inc.$79K
- plus $99K from 6 others
What the payments were for
- Consulting fees$6,91326%
- Speaking & faculty fees$10,18038%
- Travel & lodging$2,4299%
- Food & beverage$7,16827%
- Education$250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 17 | $12,085 |
| AbbVie | 164 | $10,925 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $697 |
| Johnson & Johnson(2 entities) | 30 | $608 |
| Pfizer | 34 | $457 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $386 |
| Boston Scientific | 4 | $188 |
| Ambu Inc. | 1 | $168 |
| Apollo Endosurgery US Inc | 1 | $156 |
| Olympus America Inc. | 2 | $143 |
| Medtronic | 1 | $126 |
| Cook Medical LLC | 1 | $88 |
| Sanofi | 4 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $69 |
| Dova Pharmaceuticals | 1 | $66 |
| Veloxis Pharmaceuticals, Inc. | 1 | $62 |
| Intercept Pharmaceuticals, Inc. | 4 | $60 |
| QOL Medical, LLC | 4 | $54 |
| Lilly USA, LLC | 2 | $50 |
| Boehringer Ingelheim | 2 | $31 |
| Merck | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 2 | $25 |
| Ironwood Pharmaceuticals, Inc | 2 | $25 |
| Celltrion USA Inc. | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| AstraZeneca | 1 | $19 |
| Bristol Myers Squibb | 1 | $19 |
| Ardelyx, Inc. | 1 | $14 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
| Covidien LP | 1 | $12 |
| Micro-tech Endoscopy USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$8,862
- Skyrizi$3,500
- Rinvoq$3,375
- Humira$232
- OverStitch Endoscopic Suturing System$156
- EVIS EXERA III COLONOVIDEOSCOPE$131
- GASTROINTESTINAL VIDEOSCOPE$131
- NEXPOWDER$126
- LINX Reflux Management System$116
How this compares
$26,715 in reported general payments places this provider in the 90th percentile of 133 gastroenterology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 29 | $787,149 |
| RinvoqUpadacitinib | 33 | $290,087 |
| MavyretGlecaprevir/Pibrentasvir | 12 | $184,378 |
| XifaxanRifaximin | 44 | $140,620 |
| Humira(Cf) PenAdalimumab | 18 | $133,935 |
| ZenpepLipase/Protease/Amylase | 23 | $94,094 |
| LinzessLinaclotide | 58 | $45,629 |
| ViberziEluxadoline | 12 | $18,597 |
| Pantoprazole Sodium | 631 | $6,136 |
| Budesonide EcBudesonide | 25 | $5,709 |
| Colestipol Hcl | 101 | $5,145 |
| Mesalamine | 20 | $3,399 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 192 | $3,045 |
| Mesalamine ErMesalamine | 30 | $2,855 |
| Ursodiol | 29 | $2,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $608 | $787,14929 claims |
| AbbVieRinvoq, Mavyret, Linzess, Viberzi | $10,925 | $538,689115 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $697 | $140,62044 claims |
| Aimmune Therapeutics, Inc.Zenpep | $14 | $94,09423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 133 gastroenterology providers in Oklahoma.
Other gastroenterology in Tulsa
- Jeffrey HuntTulsa$155K
- Roy ThompsonTulsa$16K
- Aaron FiekerTulsa$15K
- Vasudevan RaghuramanTulsa$14K
- William BriggsTulsa$14K
- Sheldon BergerTulsa$14K
- David MorrisTulsa$13K
- Patrick VolakTulsa$13K
- Matt BlankenshipTulsa$12K
- John HoodTulsa$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.